Snapshot · The Peter Attia Drive
HDL particles (ApoA family) account for roughly 90% of all lipoproteins in the bloodstream by number, yet carry far less total cholesterol than the smaller but larger ApoB family.
Where this was said
At 53:45 · chapter starts 53:30
Tom uses the observation that 90% of all lipoproteins are HDL particles to make a powerful point: if HDL were primarily about cholesterol transport, the body is massively overbuilt for that task. HDL cholesterol — the number everyone knows — tells us almost nothing about what HDL particles are actually doing. The real action is in the protein cargo: over 200 distinct proteins have been identified on HDL particles in peripheral circulation, each conferring different functions — anti-inflammatory, anti-oxidative, immune-modulating, coagulation-related. Because individual HDL particles are tiny, each carries only one or two of these proteins, creating a diverse army of functionally specialized HDL subpopulations. The smallest, most protein-dense HDL particles — essentially free ApoA-1 or ApoA-1 bound to one or two accessory proteins — can cross the blood-brain barrier [1] — Tom Dayspring "The brain and body run completely separate cholesterol systems. ApoB-containing particles that carry most of your plasma cholesterol are fa…" 29:05 , likely via the scavenger receptor B1, and fuse with brain ApoE HDL particles. This is how the brain receives ApoA-1 it cannot synthesize itself. If these peripheral HDL particles carry the right protective proteins, they may confer anti-inflammatory or anti-oxidative benefits inside the brain. If they are dysfunctional — carrying harmful proteins — they may worsen neurological disease.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.